NEW YORK, June 13, 2013 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("Company") (SVFC) announces that it has been
notified by the US Patent office that its patent for stem cell
extraction technology has been published. IntelliCell's proprietary
patented method for deriving blood vessel originated vascular cells
from adipose (fat) tissue by use of ultrasonic cavitation has been
made official. This technology involves an innovative mechanical
method for the separation of stromal vascular fraction cells from
adipose (fat) tissue, without the use of enzymes. Vascular cells
derived by IntelliCell's proprietary method are potentially useful
in bringing the promise of regenerative medicine to many
therapeutic and aesthetic procedures. Investors can access the
published patent at the US Patent website by entering the patent #
8,440,440. Link to patent website:
http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated
"Our Company is very pleased to announce today that with the
publishing of our patent, our technology is now protected and we
expect our international patent publication in a short time."
About IntelliCell BioSciences, Inc.
IntelliCell BioSciences is a Regenerative Medicine
company developing novel technologies that address the
regenerative, curative and preventative conditions of disease
states with high unmet clinical needs. The Company has several
patent-pending applications including the patent that was recently
published, an industry unique method of
obtaining autologous stromal vascular fraction cells
(SVF) cells from the vasculature surrounding adipose tissue
containing adult stem cells and a robust population of regenerative
healing cells. The Company is also pioneering the development
of autologous and allogeneic cells from living
and non-living tissue donors for research
purposes. IntelliCell is planning a series of in-human
clinical studies with top tier universities for the treatment of
osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and
gum regeneration in the oral cavity as well as medical aesthetics.
The Company has developed a first in class cGTP cellular
processing facility in New York City, purpose built and
designed to be fully integrated into an ambulatory surgery
center.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contacts:
Anna Rhodes, IntelliCell
BioSciences, Inc. Phone: (646) 576-8710
Email: arhodes@intellicellbiosciences.com
Melissa Diaz
, South Street Media, Inc. Phone: (917)
937-8968
Email: info@southstreetmedia.com
SOURCE IntelliCell BioSciences, Inc.